/study / lectures / Coexisting Disease
Anesthesia for Renal + Hepatic Disease
TEXTCoexisting Disease · 10 min read
Two organs that clear most of our drugs. Dosing changes, induction agent choice, fluid strategy, neuromuscular blocker selection — all hinge on knowing the failure.
After this lesson you can
2 min read7 sections- Adjust drugs for CKD/ESRD/liver disease.
- Plan fluid + electrolyte management.
- Recall sux + roc/sugammadex specifics.
- Identify dialysis-specific peri-op issues.
Renal physiology + clearance basics
CKD stage 3+ (GFR <60) needs dose adjustment for renally cleared drugs.
- K <5.5 ideal
- recent K within hours
- no AV-fistula arm BPs/IVs
- ECG for hyperK signs (peaked T, wide QRS)
Drug dosing in renal failure
- meperidine (normeperidine seizures)
- morphine (M6G accumulation → resp depression)
- gabapentin (renally cleared, severe sedation if dosed standard)
- NSAIDs
Renally cleared NMBDs to avoid in severe: pancuronium, doxacurium.
Use: cisatracurium (Hofmann elimination — organ-independent), atracurium.
Rocuronium safe (mostly hepatic).
Sugammadex safe (renal clearance slows but drug-rocuronium complex eliminated).
- fentanyl
- hydromorphone (renal accumulation of metabolites but less than morphine)
- remifentanil (ester hydrolysis — organ-independent)
Contrast-induced nephropathy + AKI prevention
- pre-existing CKD
- diabetes
- CHF
- age
- euvolemia (isotonic saline 1 mL/kg/hr 12 hr pre + post)
- hold ACEi/ARB/diuretic/NSAID periprocedure
- minimize contrast volume
N-acetylcysteine + bicarb — historically used, recent meta-analyses negative.
- MAP ≥65 (higher if baseline HTN)
- avoid prolonged hypotension
- avoid hydroxyethyl starches
- balanced crystalloid > saline (chloride-restrictive)
Hepatic disease — severity assessment
MELD score (3 labs: Cr, bili, INR) — better predictor of perioperative mortality.
MELD >15 = high risk for non-transplant surgery.
Acute hepatitis = postpone elective.
Chronic stable cirrhosis Child A can proceed with most surgery; Child C only emergent.
Drug pharmacology in liver disease
Phase-II (conjugation) preserved longer — lorazepam, oxazepam, temazepam favored.
Pseudocholinesterase reduced succinylcholine slightly prolonged.
NMBDs: cisatracurium (Hofmann) or atracurium first-line.
Hepatorenal pre-existing dose adjust both.
Cirrhosis-specific perioperative concerns
Use TEG/ROTEM rather than INR alone — cirrhotics often 'rebalanced' (both pro- and anti-coag low).
Esophageal varices — careful TEE/OGT; consider banding/treatment pre-op for elective.
Portopulmonary HTN (PVR-sensitive — manage as pulm HTN section).
Hepatopulmonary syndrome (intrapulmonary AVMs — refractory hypoxia, supplemental O2).
Ascites + reduced FRC low tidal vol, head-up.
Hypotension on induction — propofol minimally; etomidate or low-dose ketamine.
Volatile agent choice
Halothane (largely gone) historically caused halothane hepatitis.
All volatiles cause modest hepatic blood flow reduction; sevo + iso preserve splanchnic flow better than desflurane in lab studies but clinical relevance modest.
TIVA with propofol acceptable; cisatracurium-based balanced technique often preferred for advanced liver disease.
⚠ Common pitfalls
- Aggressive crystalloid in ESRD — fluid overload.
- Standard morphine in liver disease — accumulation of active metabolites.
- Aggressive normalization of INR in cirrhosis — fixing labs, not patients.
- Sux in dialysis-dependent with elevated K — significant hyperkalemia risk.
💎 Clinical pearls
- Dialysis day pre-op timing: ideally surgery day after, with stable electrolytes.
- Cisatracurium = Hofmann elimination, organ-independent — ideal in renal + hepatic failure.
- Albumin-dilution: protein-bound drugs may have free fraction increased in cirrhosis.
- Pre-op dialysis to target K <5.5 + euvolemia.
Recap
- Dialysis day pre-op timing: ideally surgery day after, with stable electrolytes.
- Cisatracurium = Hofmann elimination, organ-independent — ideal in renal + hepatic failure.
- Albumin-dilution: protein-bound drugs may have free fraction increased in cirrhosis.
- Pre-op dialysis to target K <5.5 + euvolemia.
Mark each section done to complete the module.